Velcade Consolidation Bone Study

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

April 30, 2014

Conditions
Multiple Myeloma
Interventions
DRUG

bortezomib

Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.

Trial Locations (21)

Unknown

Feldkirch

Graz

Vienna

Brno

Vejle

Hamburg

Kiel

Mÿnchen

Athens

Huddinge

Stockholm

Adana

Ankara

Antalya

Eskişehir

Gebse

Istanbul

Izmir

Edinburgh

Sheffield Yorks

Wakefield

Sponsors
All Listed Sponsors
lead

Janssen-Cilag International NV

INDUSTRY